<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">107882</article-id><article-id pub-id-type="doi">10.7554/eLife.107882</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Aging</subject></subj-group></article-categories><title-group><article-title>Multiple roles for a mitochondrial enzyme</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Xicong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0008-2434-244X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Xicong Tang</bold> is in the Cardiovascular Translational Research Center, College of Medicine-Phoenix, University of Arizona, Phoenix, United States</p></bio></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Qiu</surname><given-names>Hongyu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2436-8921</contrib-id><email>hqiu@arizona.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Hongyu Qiu</bold> is in the Cardiovascular Translational Research Center, College of Medicine-Phoenix, University of Arizona, and in Clinical Translational Sciences (CTS) and Bio5 Institution, University of Arizona, both in Phoenix, United States</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03m2x1q45</institution-id><institution>Cardiovascular Translational Research Center, College of Medicine-Phoenix, University of Arizona</institution></institution-wrap><addr-line><named-content content-type="city">Phoenix</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03m2x1q45</institution-id><institution>Clinical Translational Sciences (CTS) and Bio5 Institution, University of Arizona</institution></institution-wrap><addr-line><named-content content-type="city">Phoenix</named-content></addr-line><country>United States</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>16</day><month>06</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e107882</elocation-id><permissions><copyright-statement>© 2025, Tang and Qiu</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Tang and Qiu</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-107882-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/eLife.94794" id="ra1"/><abstract><p>The enzyme arginase-II has an important role in cardiac aging, and blocking it could help hearts stay young longer.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>aging</kwd><kwd>arginase</kwd><kwd>heart</kwd><kwd>inflammation</kwd><kwd>fibrosis</kwd><kwd>macrophages</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Rat</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The enzyme arginase-II has an important role in cardiac aging, and blocking it could help hearts stay young longer.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Potenza DM, Cheng X, Ajalbert G, Brenna A, Giraud MN, Frobert A, Cook S, Mertz KD, Yang Z, Ming XF. 2024. Cell-autonomous and non-cell-autonomous effects of arginase-II on cardiac aging. <italic>eLife</italic> <bold>13</bold>:RP94794. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.94794">10.7554/eLife.94794</ext-link>.</p></boxed-text><p>Aging is a natural biological process that causes structural and functional changes in many organs. In the heart these changes mean that its ability to pump blood declines with age, which can reduce blood flow to the entire body. Heart or cardiac aging is marked by several pathological changes, including the death of heart muscle cells (cardiomyocyte apoptosis), the accumulation of scar tissue, and reduced energy production due to mitochondrial impairment (<xref ref-type="bibr" rid="bib1">Alibhai and Li, 2024</xref>; <xref ref-type="bibr" rid="bib3">Derumeaux et al., 2024</xref>). Over time, these changes can reduce the heart’s pumping efficiency, which can lead to cardiac dysfunction or even heart failure (<xref ref-type="bibr" rid="bib10">Strait and Lakatta, 2012</xref>). Aging also increases the risk of heart diseases and makes the heart more vulnerable to ischemic injury (<xref ref-type="bibr" rid="bib8">North and Sinclair, 2012</xref>). However, the molecular mechanisms behind these changes are still not fully understood, which has hindered the development of effective therapies.</p><p>Now, in eLife, Duilio Potenza, Zhihong Yang, Xiu-Fen Ming and colleagues at the University of Fribourg report the results of experiments on mice which show that a mitochondrial enzyme called arginase-II (Arg-II; <xref ref-type="bibr" rid="bib2">Caldwell et al., 2018</xref>) has a critical role in cardiac aging (<xref ref-type="bibr" rid="bib9">Potenza et al., 2024</xref>). In particular, they show that the loss of Arg-II protects the heart against aging.</p><p>Using genetically modified mice that lack the Arg-II gene, Potenza et al. found significant protection against age-related cardiac changes. These mice showed reduced cardiomyocyte apoptosis, less accumulation of scar tissue (fibrosis), lower heart inflammation, and a reduction in endothelial-to-mesenchymal transitions. Additionally, these mice showed better resistance to ischemic injury. These observations suggest that Arg-II plays a key role in the development of age-related heart damage, making it a strong therapeutic target. This study also aligns with previous work by the same group showing that deletion of Arg-II decelerates the aging process and extends mouse lifespan (<xref ref-type="bibr" rid="bib11">Xiong et al., 2017</xref>).</p><p>Somewhat surprisingly, although Arg-II contributes to cardiac aging, the researchers also found that it is not expressed in cardiomyocytes in either aged mice or aged humans, contrary to prior assumptions. Instead, Arg-II is upregulated in other cell types, such as macrophages, fibroblasts, and endothelial cells. This suggests Arg-II may affect heart function in an indirect, yet influential, way during the aging process.</p><p>Aging is often associated with chronic, low-grade inflammation, also known as inflammaging (<xref ref-type="bibr" rid="bib5">Li et al., 2023</xref>), which can lead to the accumulation of immune cells and pro-inflammatory molecules within the heart. This accumulation can, in turn, affect the structure and function of the heart, and contribute to cardiac aging (<xref ref-type="bibr" rid="bib7">Müller and Di Benedetto, 2024</xref>; <xref ref-type="bibr" rid="bib6">Liberale et al., 2022</xref>; <xref ref-type="bibr" rid="bib4">Goldstein and Abdel-Latif, 2023</xref>), but the details of this process are not completely understood.</p><p>The study of Potenza et al. found that Arg-II increases a key inflammatory molecule, IL-1β, especially in macrophages (<xref ref-type="fig" rid="fig1">Figure 1</xref>). IL-1β then affects cardiomyocytes, fibroblasts, and endothelial cells, promoting apoptosis, fibrosis, and endothelial dysfunction. Notably, when Arg-II was deleted, levels of IL-1β went down, and the harmful effects on heart cells were reduced. As a result, heart muscle cells stopped dying, fibrosis slowed down, and endothelial cells remained healthier. In addition to highlighting IL-1β as a major link between inflammation and cardiac aging, these findings show that it is also a potential therapeutic target.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Arg-II as a driver of cardiac aging and a potential therapeutic target.</title><p>In the young heart (left), the enzyme Arg-II (red ovals) is mainly found in cells other than cardiomyocytes, such as macrophages, fibroblasts, and endothelial cells. The levels of Arg-II also increase with age. In aging hearts (right), Arg-II in macrophages promotes the release of the inflammatory molecule IL-1β (dark blue). This leads to cardiomyocyte apoptosis, fibrosis (due to excess collagen production), and an increase in the number of endothelial cells transforming into mesenchymal cells. Arg-II also increases the production of harmful reactive oxygen species (mtROS) in fibroblasts. Therefore, blocking Arg-II or its downstream effects (such as IL-1β or reactive oxygen species) could reduce damage to the heart and slow cardiac aging.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107882-fig1-v1.tif"/></fig><p>Besides showing that Arg-II promotes inflammation, Potenza et al. showed that it also boosts the production of harmful reactive oxygen species in the mitochondria of the fibroblasts. This process, which is not mediated by IL-1β, further activates fibroblasts and causes more fibrosis, indicating that Arg-II acts in different ways in different cells. Thus, Arg-II contributes to cardiac aging through both immune-mediated and cell-intrinsic mechanisms.</p><p>The study points to several potential treatments: (i) blocking Arg-II to protect the heart from aging; (ii) correcting macrophage dysfunction, possibly using cell-based therapies, to slow cardiac aging; (iii) blocking downstream mediators, such as IL-1β or reactive oxygen species, to reduce cell death, inflammation and fibrosis. By uncovering the link between Arg-II and these pathways, the study opens the door to more precise treatments for heart disease in the elderly.</p><p>The work of Potenza et al. has the potential change how we think about cardiac aging by redefining the role of Arg-II in this process. It shifts the focus away from heart muscle cells and highlights the critical influence of immune cells and other types of cells (such as macrophages, fibroblasts, and endothelial cells). It also reinforces the idea that chronic inflammation is a key driver of cardiac functional decline with age, and suggests that blocking Arg-II-mediated inflammation may offer promising strategies to prevent, or at least slow down, the heart aging process.</p><p>Further research is needed to better understand how Arg-II is upregulated in aging cells and how its effects vary between cell types. The development of cell-specific therapies will be crucial. Additionally, translating these findings from animal models to humans remains a key challenge. Nonetheless, targeting Arg-II and inflammation holds great potential for promoting healthier hearts in aging individuals.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alibhai</surname><given-names>FJ</given-names></name><name><surname>Li</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Rejuvenation of the aging heart: Molecular determinants and applications</article-title><source>Canadian Journal of Cardiology</source><volume>40</volume><fpage>1394</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2024.03.004</pub-id><pub-id pub-id-type="pmid">38460612</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caldwell</surname><given-names>RW</given-names></name><name><surname>Rodriguez</surname><given-names>PC</given-names></name><name><surname>Toque</surname><given-names>HA</given-names></name><name><surname>Narayanan</surname><given-names>SP</given-names></name><name><surname>Caldwell</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Arginase: A multifaceted enzyme important in health and disease</article-title><source>Physiological Reviews</source><volume>98</volume><fpage>641</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1152/physrev.00037.2016</pub-id><pub-id pub-id-type="pmid">29412048</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derumeaux</surname><given-names>G</given-names></name><name><surname>Sawaki</surname><given-names>D</given-names></name><name><surname>Czibik</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Trajectories in cardiac aging: Journey to the crossroads of inflammation and metabolism</article-title><source>Circulation</source><volume>149</volume><fpage>1935</fpage><lpage>1937</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.123.065116</pub-id><pub-id pub-id-type="pmid">38885299</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>DR</given-names></name><name><surname>Abdel-Latif</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Immune mechanisms of cardiac aging</article-title><source>Journal of Cardiovascular Aging</source><volume>3</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.20517/jca.2023.02</pub-id><pub-id pub-id-type="pmid">37092016</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Inflammation and aging: Signaling pathways and intervention therapies</article-title><source>Signal Transduction and Targeted Therapy</source><volume>8</volume><elocation-id>239</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-023-01502-8</pub-id><pub-id pub-id-type="pmid">37291105</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberale</surname><given-names>L</given-names></name><name><surname>Badimon</surname><given-names>L</given-names></name><name><surname>Montecucco</surname><given-names>F</given-names></name><name><surname>Lüscher</surname><given-names>TF</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Camici</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Inflammation, aging, and cardiovascular disease</article-title><source>Journal of the American College of Cardiology</source><volume>79</volume><fpage>837</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.12.017</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>L</given-names></name><name><surname>Di Benedetto</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Inflammaging, immunosenescence, and cardiovascular aging: Insights into long COVID implications</article-title><source>Frontiers in Cardiovascular Medicine</source><volume>11</volume><elocation-id>1384996</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2024.1384996</pub-id><pub-id pub-id-type="pmid">38988667</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>BJ</given-names></name><name><surname>Sinclair</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The intersection between aging and cardiovascular disease</article-title><source>Circulation Research</source><volume>110</volume><fpage>1097</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.246876</pub-id><pub-id pub-id-type="pmid">22499900</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potenza</surname><given-names>DM</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Ajalbert</surname><given-names>G</given-names></name><name><surname>Brenna</surname><given-names>A</given-names></name><name><surname>Giraud</surname><given-names>MN</given-names></name><name><surname>Frobert</surname><given-names>A</given-names></name><name><surname>Cook</surname><given-names>S</given-names></name><name><surname>Mertz</surname><given-names>KD</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Cell-autonomous and non-cell-autonomous effects of arginase-II on cardiac aging</article-title><source>eLife</source><volume>13</volume><elocation-id>RP94794</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.94794</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strait</surname><given-names>JB</given-names></name><name><surname>Lakatta</surname><given-names>EG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Aging-associated cardiovascular changes and their relationship to heart failure</article-title><source>Heart Failure Clinics</source><volume>8</volume><fpage>143</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.hfc.2011.08.011</pub-id><pub-id pub-id-type="pmid">22108734</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Yepuri</surname><given-names>G</given-names></name><name><surname>Montani</surname><given-names>JP</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Arginase-II deficiency extends lifespan in mice</article-title><source>Frontiers in Physiology</source><volume>8</volume><elocation-id>682</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2017.00682</pub-id><pub-id pub-id-type="pmid">28943853</pub-id></element-citation></ref></ref-list></back></article>